Project Grant R01MH124789
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a Project Grant totaling $129,290 on August 22, 2025, under the Mental Health Research Grants program (CFDA 93.242). This research project, extending through July 31, 2027, focuses on mapping genotype to developmental course across an autism spectrum disorder (ASD) and schizophrenia (SCZ) gradient. The Principal Investigator will analyze phenotypic, genetic, and...
- Summary The National Institute of Child Health and Human Development (NICHD) awarded a $1.75 million Cooperative Agreement to the University of Colorado-Denver on September 15, 2025, under the National Center for Advancing Translational Sciences (NCATS) program (CFDA 93.350) to establish the Network for Advancing Sex Chromosome Aneuploidy Research Readiness (NASCARR). The award funds a five-year community-based participatory research (CBPR) initiative through August 31, 2030, designed to unite...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Massachusetts General Hospital a Project Grant totaling $183,118 on September 1, 2025, under the Mental Health Research Grants program (CFDA 93.242). Under the direction of Dr. Tubbs, this research initiative will deliver integrated genomic and electronic health record (EHR) analyses designed to advance precision psychiatry by addressing critical gaps in translating genetic findings to clinical practice. The...
- Federal Cooperative Agreement Summary The National Institute of Mental Health awarded a $7.01 million Cooperative Agreement under the Mental Health Research Grants program (CFDA 93.242) to Massachusetts General Hospital for the SPARC-XP (Scalable Phenotyping to Assay Risk in Childhood After Exposures in Pregnancy) project. This four-year initiative (September 1, 2025 – August 31, 2029) will develop and validate predictive risk models to identify which offspring of mothers with infections...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $412,500 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), effective September 1, 2025, through August 31, 2027. The award funds development of a copy number variant (CNV) discovery pipeline optimized for integrated genome-exome sequencing (BGE). The research addresses a critical gap in...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the federal Mental Health Research Grants program (CFDA 93.242), supports a research project titled "RISK PATHWAYS TO MAJOR DEPRESSION: INTEGRATING GENETIC-EPIDEMIOLOGICAL, DEVELOPMENTAL, AND MOLECULAR GENETIC STRATEGIES IN DANISH AND SWEDISH NATIONAL REGISTERS." The $593,104 award, with a project period from May 1, 2025 to February 28, 2030, seeks to advance the understanding of the etiology of major...
- This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program provides $388,026 to Adelphi University to conduct research on identifying social computational phenotypes (SCPs) associated with transdiagnostic mental health spectra. The research aims to use large-scale data-driven approaches, including behavioral, computational, psychological assessment, and neuroimaging (fMRI) methods, to systematically investigate the...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $534,191 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) on April 1, 2026, through the Mental Health Research Grants program (CFDA 93.242). The award supports research through December 31, 2030, focusing on the development of robust fine-mapping tools and novel statistical methods for genetic discovery in neuropsychiatric traits using deep phenotype data....
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded a $117,747 Project Grant to The Regents of the University of California, San Francisco under the Mental Health Research Grants program (CFDA 93.242) for the period June 1, 2026 through May 31, 2028. This K99/R00 Pathway to Independence Award supports research entitled "Functional Characterization of Schizophrenia Related Risk Genes and Variants in Neurogenesis Using Cerebral Organoids." The...
- Federal Project Grant Award Summary The National Institute of Mental Health (NIMH) awarded the Regents of the University of California, San Francisco a Project Grant of $832,307 under the Mental Health Research Grants program (CFDA 93.242), with an award date of April 24, 2026, and ultimate completion date of December 31, 2030. This research initiative, titled "Genetic Control of Basal Telencephalic Development," aims to identify transcriptional and epigenetic mechanisms that control...
ROAD MAP TO PRECISION PSYCHIATRY: COMPREHENSIVE INVESTIGATION OF CHROMOSOMAL ANOMALIES (PSYCHMAP) - SUMMARY BACKGROUND: WHILE THE PAST DECADE HAS PROVIDED INSIGHT INTO THE GENETIC ARCHITECTURE OF COMPLEX TRAITS AND DISORDERS, THE IDENTIFIED GENETIC ASSOCIATIONS ARE FRAUGHT WITH COMPLEX PATTERNS OF HETEROGENEITY AND CLINICAL PLEIOTROPY, ESPECIALLY IN PSYCHIATRY. ALSO, LITTLE IS YET KNOWN ABOUT PATHOGENIC AND SOCIETAL IMPACT OF DISEASE- PREDISPOSING GENOMIC VARIANTS AT THE LEVEL OF AN INDIVIDUAL OR AN ENTIRE POPULATION, SINCE MANY OF THEM CONFER VERY MODEST INCREASES IN DISEASE RISK. RECURRENT COPY NUMBER VARIANTS (CNVS) AND SEX CHROMOSOME ANEUPLOIDIES (SCAS) ARE WELL SUITED TO BREAK THE IMPASSE AND PILOT EFFORTS IN PRECISION PSYCHIATRY WITH THEIR REASONABLE PREVALENCE AND SIZABLE DISEASE RISK. AIMS: WE WILL FIRST PROVIDE TRULY UNBIASED ESTIMATES OF PREVALENCE, AS WELL AS AGE-DEPENDENT HAZARD AND DISEASE PENETRANCE, OF RECURRENT CNVS AND SCA; SECOND, DETERMINE THE GLOBAL BURDEN OF DISEASE (GBD) OF THESE GENOMIC ALTERATIONS; AND THIRD, TRANSFORM THESE FINDINGS INTO CLINICAL RECOMMENDATIONS FOR ACTIONABLE GENETIC TESTING AND PLANNING OF HEALTHCARE PROVISION. ADDITIONALLY, WE WILL DETERMINE THE DEGREE TO WHICH PATHOLOGIC PROFILES OF CNV/SCA DIFFER BETWEEN CLINICALLY ASCERTAINED CARRIERS (WHO FORM THE BASIS OF MOST HITHERTO RESEARCH OF PATHOGENICITY OF CNVS/SCAS) AND CARRIERS WHOSE CARRIER STATUS IS UNKNOWN BY THE HEALTHCARE SYSTEM. METHODS: WE WILL (A) LEVERAGE A GENOTYPED CASE-COHORT PSYCHIATRIC SAMPLE TRULY REPRESENTATIVE OF THE DANISH POPULATION (N[PSYCH]=90.000; N[COHORT]=50,000) TO DETERMINE CARRIER STATUS OF RECURRENT CNVS AT 54 GENOMIC LOCI AS WELL AS FOR SCA, (B) CROSS-REFERENCE DETAILED CLINICAL, DEMOGRAPHIC AND SOCIO-ECONOMIC PERSON-LEVEL DATA FROM PUBLIC, NATIONWIDE REGISTRIES, IN ORDER TO (C) ESTIMATE FOR EACH OF THE CHROMOSOMAL ANOMALIES (I) THE POPULATION PREVALENCE, PENETRANCE AND HAZARDS FOR INDIVIDUAL PSYCHIATRIC AND SOMATIC DIAGNOSES, (II) THE CORRESPONDING LIFE-TIME DISEASE TRAJECTORIES AND (III) THE DISEASE BURDEN, USING (D) (I) COX PROPORTIONAL HAZARDS MODELS WITH INVERSE SAMPLING PROBABILITY WEIGHTS, (II) SEQUENCE ANALYSIS AND (III) STANDARD HEALTH ECONOMIC MEASURES, INCL. DALY AND DIRECT AND INDIRECT HEALTHCARE COSTS. SOME OF THESE METHODS HAVE BEEN DEVELOPED SPECIFICALLY OVER THE LAST YEARS IN COOPERATION BETWEEN THE RESEARCH GROUPS OF THE DANISH AND U.S. BASED APPLICANTS. TO DETERMINE THE IMPACT OF ASCERTAINMENT BIAS ON PERCEIVED DISEASE RATES OF CARRIERS, WE'LL CROSS- REFERENCE THE DANISH POPULATION SAMPLE CARRIERS WITH RECORDS FROM THE DANISH CYTOGENETIC REGISTER AND COMPARE CLINICALLY KNOWN VS. UNKNOWN CARRIERS, AND ALSO COMPARE OVERALL DISEASE RATE IN THE DANISH POPULATION SAMPLE CARRIERS WITH A LARGE CLINICAL SAMPLE OF SCA CARRIERS FROM THE U.S.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $522.3k | 4/27/26 | ||
| Not listed | $0 | 2/27/26 | ||
| Not listed | $0 | 2/27/26 | ||
| Not listed | $522.3k | 9/25/25 | ||
| Not listed | $522.3k | 9/25/25 |